Cocrystal Pharma
COCP
21 hedge funds and large institutions have $7.01M invested in Cocrystal Pharma in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
11,408% more capital inflows, than outflows
Capital inflows: $4.71M | Capital outflows: $40.9K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
11% more funds holding
Funds holding: 19 → 21 (+2)
5.12% more ownership
Funds ownership: 3.72% → 8.84% (+5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.17M |
| 2 |
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$118K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$45.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Panagora Asset Management
Boston,
Massachusetts
|
-$14.5K |
| 2 |
Morgan Stanley
New York
|
-$13.7K |
| 3 |
BlackRock
New York
|
-$6.4K |
| 4 |
Jane Street
New York
|
-$4.32K |
| 5 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$2K |
COCP Hedge Fund Activity: Q1 2019 in Review
21 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2019, worth a combined $7.01M — up 75% from $4.01M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new COCP positions and 1 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $2.17M. The largest seller was Panagora Asset Management, cutting an estimated $14.5K.
- 21 institutional investors held Cocrystal Pharma (COCP) as of Q1 2019, up from 19 in Q4 2018.
- Funds reported $7.01M of Cocrystal Pharma stock for Q1 2019, up 75% quarter-over-quarter.
- 3 funds opened new Cocrystal Pharma positions in Q1 2019 and 1 closed out, a net change of +2 holders.
- The largest Cocrystal Pharma buyer in Q1 2019 was Royal Bank of Canada, an estimated $2.17M added.
- The largest Cocrystal Pharma seller in Q1 2019 was Panagora Asset Management, an estimated $14.5K sold.
Based on aggregated 13F filings for Q1 2019.